New Delhi, July 11 -- Wockhardt Ltd is exiting its loss-making US generics business, as it focuses on its new antibiotics drug discovery and insulin portfolios.

The drugmaker said on Friday that it has made a Chapter 7 filing for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. The business has been incurring losses over the past several years, clocking nearly $8 million losses in FY25.

In an interview with Mint in April, Wockhardt chairman Habil Khorakiwala had said the company is planning to exit the US generics segment, in a move to "derisk the organization fundamentally". The company will continue to run its pharmaceutical operations in India, the UK, Ireland, and other geographie...